His scientific interests lie mostly in Immunology, Cancer, Cancer research, Immunotherapy and Cancer cell. He interconnects Cytotoxic T cell and Breast cancer in the investigation of issues within Immunology. His Cancer study combines topics in areas such as Immunohistochemistry, Lung cancer and Pathology.
His Cancer research study combines topics from a wide range of disciplines, such as Side population, Survivin and Sarcoma. As a part of the same scientific family, Toshihiko Torigoe mostly works in the field of Immunotherapy, focusing on Antigen and, on occasion, Antibody, Molecular biology and Extracellular. His Colorectal cancer research includes themes of Tumor progression and Oncology.
Toshihiko Torigoe mostly deals with Cancer research, Immunology, Cancer, Antigen and Immunotherapy. Toshihiko Torigoe works mostly in the field of Cancer research, limiting it down to topics relating to Cancer cell and, in certain cases, Side population. His study ties his expertise on Survivin together with the subject of Immunology.
The concepts of his Cancer study are interwoven with issues in Carcinoma, Pathology and Oncology. His research integrates issues of Cytotoxic T cell, Molecular biology and Cell biology in his study of Antigen. The various areas that he examines in his Immunotherapy study include Adoptive cell transfer, HLA-A24 and Melanoma.
Toshihiko Torigoe mainly investigates Cancer research, Internal medicine, Immune system, Cancer and Oncology. His work deals with themes such as Cancer cell, Cancer stem cell, Human leukocyte antigen, Antigen and Immunotherapy, which intersect with Cancer research. As part of one scientific family, Toshihiko Torigoe deals mainly with the area of Internal medicine, narrowing it down to issues related to the Gastroenterology, and often Brain metastasis, Progressive disease and Exacerbation.
The subject of his Immune system research is within the realm of Immunology. The study incorporates disciplines such as Stage, Surgery, Phenotype and Pathology in addition to Cancer. His studies in Oncology integrate themes in fields like Tegafur, Gemcitabine and Clinical endpoint.
Internal medicine, Oncology, Cancer, Cancer research and Immune system are his primary areas of study. His Internal medicine study incorporates themes from Mucosal melanoma and Cutaneous melanoma. His work carried out in the field of Oncology brings together such families of science as Colorectal cancer and Clinical endpoint.
His Cancer research incorporates themes from Disease and Antigen. His research in Cancer research intersects with topics in Carcinogenesis, Cell and Cell culture, Gene knockdown. CTL* is a subfield of Immunology that Toshihiko Torigoe tackles.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
Franck Pagès;Bernhard Mlecnik;Florence Marliot;Gabriela Bindea;Gabriela Bindea;Gabriela Bindea.
The Lancet (2018)
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.
Jérôme Galon;Jérôme Galon;Jérôme Galon;Bernhard Mlecnik;Bernhard Mlecnik;Bernhard Mlecnik;Gabriela Bindea;Gabriela Bindea;Gabriela Bindea;Helen K. Angell;Helen K. Angell;Helen K. Angell.
The Journal of Pathology (2014)
Cancer classification using the Immunoscore: a worldwide task force
Jérôme Galon;Franck Pagès;Francesco M Marincola;Francesco M Marincola;Helen K Angell;Helen K Angell.
Journal of Translational Medicine (2012)
Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Hiroyuki Komori;Tetsuya Nakatsura;Satoru Senju;Yoshihiro Yoshitake.
Clinical Cancer Research (2006)
Aberrant Expression and Potency as a Cancer Immunotherapy Target of Inhibitor of Apoptosis Protein Family, Livin/ML-IAP in Lung Cancer
Hiroyuki Hariu;Yoshihiko Hirohashi;Toshihiko Torigoe;Hiroko Asanuma.
Clinical Cancer Research (2005)
Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Hiroko Asanuma;Toshihiko Torigoe;Kenjiro Kamiguchi;Yoshihiko Hirohashi.
Cancer Research (2005)
An HLA-A24-restricted Cytotoxic T Lymphocyte Epitope of a Tumor-associated Protein, Survivin
Yoshihiko Hirohashi;Toshihiko Torigoe;Akiko Maeda;Yuki Nabeta.
Clinical Cancer Research (2002)
Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer
Tetsuhiro Tsuruma;Fumitake Hata;Toshihiko Torigoe;Tomohisa Furuhata.
Journal of Translational Medicine (2004)
CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
Noriyuki Yamada;Satoshi Oizumi;Eiki Kikuchi;Naofumi Shinagawa.
Cancer Immunology, Immunotherapy (2010)
Detection of autoantibodies to livin and survivin in Sera from lung cancer patients.
Atsuhito Yagihashi;Koichi Asanuma;Daisuke Kobayashi;Naoki Tsuji.
Lung Cancer (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: